BMX Crystal Forms for Controlled Polymorphism and Drug Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing preparation method of Compound BMX does not account for its potential polymorphism, which affects the quality, therapeutic efficacy, and formulation processing performance, necessitating the development of new crystal forms to enhance solubility, stability, and bioavailability.
Innovation Solution
The development of novel crystal forms A, B, C, D, E, and G of Compound BMX, characterized by specific X-ray powder diffraction patterns and Differential Scanning Calorimetry profiles, is achieved through controlled precipitation, solvent evaporation, and slurry methods using various solvents and anti-solvents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the existing preparation method of Compound BMX is used, then the compound can be synthesized, but the polymorphism and crystal form characteristics are not controlled, leading to inconsistent quality and therapeutic efficacy
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions including solvent types (ethyl acetate, n-hexane, dichloromethane, methanol, water), temperatures (0-5°C, room temperature, 50°C), and processing methods (slow addition, fast evaporation, slurry treatment) to obtain different crystal forms (A-G) of Compound BMX, each with distinct XRPD patterns and therapeutic properties
Solution Approach 2:
The patent employs preliminary action through seed crystal addition and pre-equilibration steps. For example, seed crystals are added before crystallization to guide the formation of specific polymorphs, and slurries are pre-prepared with specific solvents and anti-solvents to ensure controlled crystal growth and consistent quality
2Ease of operation
If different crystal forms of Compound BMX are developed, then solubility and bioavailability can be improved, but the formulation processing complexity increases
Solution Approach 1:
The patent utilizes inexpensive and readily available solvents such as ethyl acetate, n-hexane, dichloromethane, methanol, and water for crystallization processes. These common laboratory solvents enable easy reproduction of crystal forms without requiring specialized or expensive materials, simplifying formulation processing
Solution Approach 2:
The patent exploits phase transitions during crystallization by controlling temperature changes (cooling from 50°C to 0-5°C), solvent evaporation rates, and anti-solvent addition to induce controlled precipitation of different crystal forms. The DSC analysis confirms distinct phase transition temperatures for each polymorph, enabling quality control
3Measurement precision
If crystal forms are characterized using multiple analytical methods, then the quality control is enhanced, but the detection and measurement difficulty increases
Solution Approach 1:
The patent segments the characterization process into distinct analytical methods, each targeting specific properties: XRPD for crystal structure identification (distinct peak patterns for forms A-G), DSC for thermal properties (different melting and recrystallization temperatures), and TGA for stability assessment. This segmentation allows systematic quality control without overwhelming complexity
Solution Approach 2:
While not directly applying color changes, the patent uses analogous detection principles where XRPD produces distinct diffraction patterns (analogous to color signatures) for each crystal form, enabling rapid identification. The characteristic peak positions and intensities serve as fingerprints for quality control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new crystal forms exhibit distinct thermal and solubility properties, with Crystal Form A being the most stable, improving the drug's quality and formulation processing, and providing a basis for stable pharmaceutical compositions.
Implementation Method 1
an X-ray powder diffraction pattern (XRPD) having peaks 2θ of about 4.58°, 7.58°, 9.14°, 11.30°, 12.41°, 13.71°, 15.05°, 15.41°, 16.27°, 16.97°, 18.44°, 19.16°, 19.51°, 19.87°, 20.49°, 22.71°, 22.92°, 23.33°, 23.86°, 24.92°, 25.55°, 26.36°, 27.58°, 28.00°, 28.48°, 28.77°, 29.38°, and 30.32°
Implementation Method 2
an X-ray powder diffraction pattern (XRPD) having peaks
Implementation Method 3
an infrared spectrum having characteristic absorption peaks at about 3250, 2909, 2837, 1643, 1590, 1515, 1484, 1462, 1250, 1173, 1088, 991, 823, 806, 796, 516 and 481 cm−1
Implementation Method 4
a Differential Scanning Calorimetry (DSC) pattern having a sharp single melt at T peak=137.8° C. and a recrystallization event at T peak=155.1° C.
Implementation Method 5
a sharp single melt at T peak=137.8° C. and a recrystallization event at T peak=155.1° C
Implementation Method 6
slowly adding n-hexane with stirring and cooling it to a room temperature to obtain a solution; cooling the solution to 0 ∼5° C. for accelerating precipitation to obtain the Crystal Form A
Implementation Method 7
fast evaporating the solution obtained in the above step to obtain an amorphous material of Compound BMX
Data Source
AI summary
The present invention relates to some crystal forms for a cinnamic compound, BMX, which is an inhibitor of histone deacetylase (HDAC), useful as an agent for the prevention or treatment of diseases associated with HDAC, including for treating tumor or cell proliferative diseases, diabetes mellitus, or neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Spinocerebellar Ataxias (SCA) and human spinal muscular atrophy (SMA). Also provided are a method for preparing the crystal forms and pharmaceutical compositions comprising the crystal forms.